1. Home
  2. KGS vs BLTE Comparison

KGS vs BLTE Comparison

Compare KGS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Gas Services Inc.

KGS

Kodiak Gas Services Inc.

HOLD

Current Price

$64.92

Market Cap

6.8B

Sector

N/A

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$150.47

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGS
BLTE
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.0B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
KGS
BLTE
Price
$64.92
$150.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$57.17
$198.00
AVG Volume (30 Days)
1.7M
192.7K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
2.93%
N/A
EPS Growth
58.93
N/A
EPS
0.20
N/A
Revenue
$1,308,100,000.00
N/A
Revenue This Year
$12.30
N/A
Revenue Next Year
$7.96
$492.11
P/E Ratio
$330.00
N/A
Revenue Growth
12.83
N/A
52 Week Low
$30.06
$59.12
52 Week High
$77.68
$200.00

Technical Indicators

Market Signals
Indicator
KGS
BLTE
Relative Strength Index (RSI) 41.39 52.02
Support Level $55.10 $146.60
Resistance Level $77.13 $151.41
Average True Range (ATR) 2.99 7.16
MACD -0.58 -0.10
Stochastic Oscillator 11.50 52.94

Price Performance

Historical Comparison
KGS
BLTE

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: